(20 Apr 2021) EpAbs (INM005)- mortality was 6*9% the INM005 group Vs 11*4% in the placebo
RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial https://doi.org/10.1016/j.eclinm.2021.100843 NCT04494984-Enrolled patients were assigned to receive two blinded doses of INM005 (n =… Continue reading "(20 Apr 2021) EpAbs (INM005)- mortality was 6*9% the INM005 group Vs 11*4% in the placebo"